We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock

Delisted

EVFM was delisted on the 10th of August, 2022.

42 hedge funds and large institutions have $147M invested in Evofem Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

17% more funds holding

Funds holding: 3642 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

24% less capital invested

Capital invested by funds: $194M → $147M (-$46.1M)

Holders
42
Holders Change
+6
Holders Change %
+16.67%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
13
Reduced
10
Closed
4
Calls
$504K
Puts
Net Calls
+$504K
Net Calls Change
-$160K
Name Holding Trade Value Shares
Change
Change in
Stake
WIM
1
Woodford Investment Management
United Kingdom
$63M -$6.34M -82,508 -9%
Invesco
2
Invesco
Georgia
$59.5M
JAM
3
Jupiter Asset Management
United Kingdom
$6.24M +$6.34M +82,508 New
HA
4
Heartland Advisors
Wisconsin
$4.54M +$256K +3,333 +6%
BlackRock
5
BlackRock
New York
$3.84M +$119K +1,556 +3%
TWMP
6
Taylor Wealth Management Partners
Massachusetts
$2.68M -$8.06K -105 -0.3%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.1M -$1.23M -16,019 -37%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.42M +$845 +11 +0.1%
State Street
9
State Street
Massachusetts
$1.06M +$109K +1,414 +11%
Northern Trust
10
Northern Trust
Illinois
$950K +$593K +7,718 +159%
BBA
11
Baker Bros. Advisors
New York
$514K +$522K +6,803 New
N
12
Nuveen
North Carolina
$188K
Bank of New York Mellon
13
Bank of New York Mellon
New York
$156K -$7.45K -97 -4%
Charles Schwab
14
Charles Schwab
California
$149K -$77.2K -1,005 -34%
Wells Fargo
15
Wells Fargo
California
$111K +$112K +1,461 +20,871%
California State Teachers Retirement System (CalSTRS)
16
California State Teachers Retirement System (CalSTRS)
California
$110K
State of Wisconsin Investment Board
17
State of Wisconsin Investment Board
Wisconsin
$107K +$109K +1,420 New
Millennium Management
18
Millennium Management
New York
$79K +$81.2K +1,057 New
Renaissance Technologies
19
Renaissance Technologies
New York
$78K +$79.3K +1,033 New
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$77K
UBS Group
21
UBS Group
Switzerland
$57K +$42.4K +552 +288%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$54K +$614 +8 +1%
PPA
23
Parametric Portfolio Associates
Washington
$53K +$54.2K +706 New
AIG
24
American International Group
New York
$45K -$307 -4 -0.7%
Barclays
25
Barclays
United Kingdom
$35K -$10.9K -142 -23%

EVFM Hedge Fund Activity: Q3 2019 in Review

42 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2019, worth a combined $147M — down 24% from $194M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EVFM positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Jupiter Asset Management, opening a new position worth an estimated $6.34M. The largest seller was Woodford Investment Management, cutting an estimated $6.34M.

  • 42 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2019, up from 36 in Q2 2019.
  • Funds reported $147M of Evofem Biosciences, Inc. Common Stock stock for Q3 2019, down 24% quarter-over-quarter.
  • 10 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of +6 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2019 was Jupiter Asset Management, an estimated $6.34M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2019 was Woodford Investment Management, an estimated $6.34M sold.

Based on aggregated 13F filings for Q3 2019.